All Oncology News

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

Envafolimab plus suvemcitug and FOLFIRI demonstrated preliminary activity and tolerability in second-line MSS/pMMR CRC.

Adam Duvall, MD, MPH, spotlights new research further elucidating the role of blinatumomab in the acute lymphoblastic leukemia treatment paradigm.

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Yale Medicine was ranked third in the nation for physician practices, an annual designation by Castle Connolly.

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

A chatbot-based approach was equivalent to SOC pretest cancer genetic services and genetic testing among individuals eligible for cancer genetic testing.

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Get the inside scoop from Drs Lou, Patel, and Beg on the top takeaways to come out of the 2025 Gastrointestinal Cancers Symposium.

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

The European Commission has approved serplulimab in combination with carboplatin and etoposide for the frontline treatment of adult patients with ES-SCLC.

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

Sattava S. Neelapu, MD, discusses updated data from the 5-year follow-up analysis evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Optimized T-cell manufacturing is one strategy that may prevent SPCs after CAR T-cell therapy, according to Shyam A. Patel, MD, PhD, and Saurabh Dahiya, MD, FACP.

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

Eric Goodlev, MD, associate professor in the supportive oncology and palliative care program, was recently named a Fellow of the American Academy of Hospice and Palliative Medicine.

THIO plus cemiplimab generated a potential survival benefit in pretreated advanced non–small cell lung cancer.

The EMA’s CHMP has issued a positive opinion supporting the approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

UF-Kure19, a rapidly manufactured CAR T-cell therapy, generated an 80% complete response rate in relapsed/refractory non-Hodgkin lymphoma.